Y-mAbs Therapeutics is a clinical‐stage biopharmaceutical company focused on developing antibody-based cancer immunotherapies for pediatric and adult patients. Leveraging proprietary antibody engineering and radiolabeling platforms, the company targets solid tumors and central nervous system malignancies that express the GD2 antigen. Its research approach combines monoclonal antibodies with radioconjugates to selectively deliver therapeutic payloads to cancer cells.
The company’s lead product, DANYELZA (naxitamab-gqgk), received U.S. Food and Drug Administration approval in 2020 for the treatment of high-risk neuroblastoma in pediatric and young adult patients whose disease has not progressed after multi-cycle chemotherapy. In addition to its marketed therapy, Y-mAbs is advancing omburtamab, a radiolabeled monoclonal antibody designed to target metastatic or leptomeningeal tumors in the central nervous system. The pipeline also includes earlier-stage antibody candidates exploring novel targets in solid tumors.
Headquartered in New York, Y-mAbs is domiciled in Switzerland and conducts clinical trials across North America, Europe and Australia. Commercial operations for DANYELZA extend into the United States and Canada, with expanded access programs facilitating treatment for patients outside traditional trial settings. Through collaborations with leading research institutions, the company continues to broaden its development footprint in pediatric oncology.
Founded in 2016 out of collaborative research efforts, Y-mAbs operates under a management team with extensive experience in oncology drug development and regulatory strategy. The company’s scientific leadership and board comprise veterans of both large-cap pharmaceutical firms and specialized biotech startups, supporting its mission to bring targeted immunotherapies to underserved cancer populations.
AI Generated. May Contain Errors.
Free YMAB Stock Alerts